ABBOTT LABORATORIES (ABT) FY2024 Q3 Balance Sheet

ABBOTT LABORATORIES (ABT) FY2024 Q3 Balance Sheet

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

Assets

74,356,000,000 US dollars

Current assets

23,802,000,000 US dollars

Non-current assets

50,554,000,000 US dollars

Liabilities (calculated)

34,328,000,000 US dollars

Current liabilities

14,902,000,000 US dollars

Non-current liabilities

19,426,000,000 US dollars

Equity

40,028,000,000 US dollars

Noncontrolling interest

232,000,000 US dollars. Included in consolidated equity; this amount is not added again.

Property and equipment, at cost

22,857,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Less: accumulated depreciation and amortization

negative 12,236,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.

Cash and cash equivalents

7,558,000,000 US dollars

Trade receivables, less allowances of $456 in 2024 and $444 in 2023

7,051,000,000 US dollars

Finished products

4,173,000,000 US dollars

Prepaid expenses and other receivables

2,150,000,000 US dollars

Materials

1,763,000,000 US dollars

Work in process

877,000,000 US dollars

Short-term investments

230,000,000 US dollars

Goodwill

23,658,000,000 US dollars

Net property and equipment

10,621,000,000 US dollars

Deferred income taxes and other assets

8,011,000,000 US dollars

Intangible assets, net of amortization

7,352,000,000 US dollars

Investments

912,000,000 US dollars

Other accrued liabilities

5,427,000,000 US dollars

Trade accounts payable

4,034,000,000 US dollars

Current portion of long-term debt

2,154,000,000 US dollars

Salaries, wages and commissions

1,618,000,000 US dollars

Dividends payable

956,000,000 US dollars

Income taxes payable

713,000,000 US dollars

Long-term debt

12,825,000,000 US dollars

Post-employment obligations, deferred income taxes and other long-term liabilities

6,601,000,000 US dollars

Earnings employed in the business

39,056,000,000 US dollars

Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,991,051,414; 2023: 1,987,883,852

25,020,000,000 US dollars

Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued

0 US dollars

Noncontrolling Interests in Subsidiaries

232,000,000 US dollars

Common shares held in treasury, at cost — Shares: 2024: 256,595,476; 2023: 253,807,494

negative 16,476,000,000 US dollars

Accumulated other comprehensive income (loss)

negative 7,804,000,000 US dollars

Gross equity (calculated)

64,308,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.